Award
NIH Reporter #5R42NS098918-06
A Novel Xenon Delivery Platform for Cerebroprotection During Stroke
Recipient
ZYMO RESEARCH CORPORATION
Award Amount
$907,735.00
Ceiling
$907,735.00
Awarded
August 11, 2026
Identifier
5R42NS098918-06
The award funds research on a novel Xenon-Liposome delivery platform to protect the brain during acute ischemic stroke, aiming to improve treatment outcomes and extend therapy windows through clinical validation and regulatory preparation.
Description
This project explores a new approach to stroke treatment involving intermittent administration of Xenon-Liposome (XKS07) for acute ischemic stroke (AIS). The strategy aims to induce natural brain protection and extend the window for reperfusion therapy, with benefits including epigenetic influences on long-term recovery. The project involves validating the lead product in clinical models, developing pharmacokinetic models, and preparing for FDA IND submission to enable Phase I and II clinical trials.